Admissions and Cost of Hospitalisation of Phenylketonuria: Spanish Claims Database Analysis
- PMID: 30778886
- DOI: 10.1007/s40261-019-00760-1
Admissions and Cost of Hospitalisation of Phenylketonuria: Spanish Claims Database Analysis
Abstract
Background: Phenylketonuria is a well-known rare disease included in the neonatal screening of many countries. Therefore, there are few published data on the admissions and costs of phenylketonuria in Spain.
Objective: The objective of this study was to assess the number of admissions and the economic burden of phenylketonuria in Spain.
Methods: Patients with phenylketonuria were identified from a Spanish database containing data from public and private healthcare centres from 1997 to 2015. The parameters obtained were characteristics of the patients, type of admissions, readmissions, discharges, length of stay, medical service, annual number of visits, annual number of patients, visit-associated costs and patient-associated costs.
Results: Five hundred and ninety-four patients with phenylketonuria were identified: 48.32% were male with a mean (standard deviation) age of 4.50 (10.23) years. The hospital admissions were divided into emergency visits (55.94%) and scheduled visits (43.92%). The majority of patients were discharged home (98.86%). The mean (standard deviation) duration of stay was 4.04 (4.98) days. The number of admissions per year ranged between 13 and 88, with an average of 1.18 admissions per patient per year. Finally, the mean cost per visit increased from €1064.91 to €3709.40, and the mean cost per patient increased from €1818.90 to €4239.32 from 1999 to 2015.
Conclusions: The access to economic and social data on phenylketonuria in Spain has been updated. The number of admissions in Spain between 1997 and 2015 and healthcare costs between 1999 and 2015 were calculated. There were 24 admissions as a result of a phenylketonuria diagnosis in 2015 and the mean healthcare cost per patient was €4239.32. This information can help to adapt and improve each healthcare system to take into consideration rare diseases.
Similar articles
-
Characteristics, comorbidities, and use of healthcare resources of patients with phenylketonuria: a population-based study.J Med Econ. 2019 Oct;22(10):1025-1029. doi: 10.1080/13696998.2019.1636381. Epub 2019 Jul 11. J Med Econ. 2019. PMID: 31237171
-
Economic impact of dry eye disease in Spain: A multicentre retrospective insurance claims database analysis.Eur J Ophthalmol. 2021 Mar;31(2):328-333. doi: 10.1177/1120672120907315. Epub 2020 Feb 16. Eur J Ophthalmol. 2021. PMID: 32064919
-
Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis.BMJ Open. 2019 Nov 21;9(11):e031271. doi: 10.1136/bmjopen-2019-031271. BMJ Open. 2019. PMID: 31753879 Free PMC article.
-
Nationwide trends in inpatient admissions of pulmonary hypertension in the United States from 2000 to 2013.Adv Respir Med. 2017;85(2):77-86. doi: 10.5603/ARM.2017.0014. Adv Respir Med. 2017. PMID: 28440533
-
Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms.Ann Am Thorac Soc. 2019 Jul;16(7):797-806. doi: 10.1513/AnnalsATS.201810-672CME. Ann Am Thorac Soc. 2019. PMID: 30865835 Free PMC article. Review.
Cited by
-
Professional activity, gender and disease-related emotions: The impact on parents' experiences in caring for children with phenylketonuria.Mol Genet Metab Rep. 2023 Jul 15;36:100992. doi: 10.1016/j.ymgmr.2023.100992. eCollection 2023 Sep. Mol Genet Metab Rep. 2023. PMID: 37502286 Free PMC article.
-
Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai.Orphanet J Rare Dis. 2019 Oct 22;14(1):233. doi: 10.1186/s13023-019-1168-4. Orphanet J Rare Dis. 2019. PMID: 31640704 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical